Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States and internationally. The company’s lead products include INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2) used for the treatment of movement disorders; elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that is in Phase III clinical trials used for women’s health; and opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trials used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson’s disease. It is also developing NBI-640756 that is in Phase I clinical trials used for the treatment of essential tremor; and NBI-74788, which is in Phase I clinical trials used for the treatment of classic congenital adrenal hyperplasia. In addition, the company’s research programs comprise VMAT2 Inhibitors for movement disorders, bipolar disorders, and schizophrenia; and G Protein-Coupled Receptors and Ion Channels for epilepsy, essential tremor, pain, and other Indications. It has collaborations with AbbVie Inc. to develop and commercialize elagolix and GnRH antagonists for women’s and men’s health; Mitsubishi Tanabe Pharma Corporation to develop and commercialize INGREZZA for movement disorders; and BIAL Portela & Ca, S.A. to develop and commercialize opicapone for the treatment of human diseases and conditions, including Parkinson’s disease. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.

  • Does Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) CEO Pay Reflect Performance?
    on July 15, 2019 at 2:17 pm

    Kevin Gorman became the CEO of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) in 2008. This analysis aims first to... […]

  • FDA Accepts Neurocrine's NDA for Parkinson's Disease Drug
    on July 11, 2019 at 3:14 pm

    The FDA accepts Neurocrine's (NBIX) NDA for opicapone, developed as an adjunctive treatment to levodopa/carbidopa for patients with Parkinson's disease, who currently experience OFF episodes. […]

  • The Daily Biotech Pulse: Neurocrine's Parkinson's Drug Accepted For Review, Sunesis Offering, No Headaches For Biohaven's Migraine Drug
    on July 11, 2019 at 10:17 am

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 10) CONMED Corporation (NASDAQ: CNMD ) Eidos Therapeutics ... […]

  • Neurocrine Biosciences Announces FDA Acceptance of New Drug Application for Opicapone as an Adjunctive Treatment for Patients with Parkinson's Disease
    on July 10, 2019 at 8:10 pm

    SAN DIEGO, July 10, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for opicapone, a novel, once-daily, oral, selective catechol-O-methyltransferase (COMT) inhibitor as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing OFF episodes. Parkinson's disease is a chronic, progressive and debilitating neurodegenerative disorder that affects approximately one million people in the U.S. The FDA has set a standard 12-month review process with a Prescription Drug User Fee Act (PDUFA) target action date of April 26, 2020. […]

  • 9 Health-Care Stocks for Your Portfolio
    on July 9, 2019 at 9:02 pm

    Part defense, part offense and all bargain, health care stocks should thrive. […]

  • Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2019 Financial Results
    on July 8, 2019 at 8:01 pm

    Conference Call and Webcast Scheduled for Monday, July 29 SAN DIEGO , July 8, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it will report second quarter financial ... […]

  • See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.
    on June 18, 2019 at 12:04 pm

    Neurocrine Biosciences Inc NASDAQ/NGS:NBIXView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for NBIX with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding NBIX are favorable, with net inflows of $3.31 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report. […]

  • Neurocrine Biosciences to Present Data on INGREZZA® (valbenazine) and Opicapone at the 2019 World Congress on Parkinson's Disease and Related Disorders
    on June 11, 2019 at 8:01 pm

    SAN DIEGO, June 11, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) today announced it will present data from two of its movement disorder programs, including INGREZZA® (valbenazine) capsules, the first U.S. Food and Drug Administration (FDA) approved treatment for adults with tardive dyskinesia (TD), and opicapone, an investigational adjunct treatment for Parkinson's disease. Analyses include long-term data on INGREZZA in adult patients with TD, a disorder characterized by uncontrollable, abnormal and repetitive movements of the face, torso and/or other body parts, which may be disruptive and negatively impact patients. […]

  • Hedge Funds Are Dumping Neurocrine Biosciences, Inc. (NBIX)
    on June 11, 2019 at 5:49 pm

    There are several ways to beat the market, and investing in small cap stocks has historically been one of them. We like to improve the odds of beating the market further by examining what famous hedge fund operators such as Jeff Ubben, George Soros and Carl Icahn think. Those hedge fund operators make billions of […]

  • Neurocrine Biosciences to Present at Goldman Sachs 40th Annual Global Healthcare Conference
    on June 4, 2019 at 8:01 pm

    Live Audio Webcast will be on June 11, 2019 SAN DIEGO , June 4, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) will present at the Goldman Sachs 40 th Annual Global Healthcare Conference ... […]

3 days ago

Alignmt LLC

Cultivate your brand value throughout relevant #financial and #industry communities. And remember: never neglect your #stakeholders. #alignmentmap ... See MoreSee Less

View on Facebook

3 days ago

Alignmt LLC

Got #investors? Want to know what's on their minds? Good #investorrelations starts with them. #alignmentmap ... See MoreSee Less

View on Facebook

3 days ago

Alignmt LLC

Want to share relevant facts about how your business is developing to the people who back you?

Check out the 7 insightful questions #investorrelations must answer. Check out ways to improve your business results with an #alignmentmap at
... See MoreSee Less

View on Facebook

3 days ago

Alignmt LLC

What's one thing you wish somebody would have told you before getting into this business? #alignmentmap ... See MoreSee Less

View on Facebook

Want to maximize your business valuation? First things first when thinking about selling.

Load More...

    Feed has no items.

Neurocrine Biosciences, Inc.

12780 El Camino Real
San Diego, CA 92130

+1 (858) 617-7600

July 2019
« Apr    

©2019 ALIGNMT LLC | Alignment Consulting | Mergers & Acquisitions | Investor Relations


We're not around right now. But you can send us an email and we'll get back to you, asap.


Log in with your credentials


Forgot your details?

Create Account